Pyxis Oncology Stock Performance
| PYXS Stock | USD 1.22 0.06 4.69% |
The company holds a Beta of 0.88, which implies possible diversification benefits within a given portfolio. Pyxis Oncology returns are very sensitive to returns on the market. As the market goes up or down, Pyxis Oncology is expected to follow. At this point, Pyxis Oncology has a negative expected return of -0.63%. Please make sure to check Pyxis Oncology's potential upside and day median price , to decide if Pyxis Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pyxis Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 180.8 M |
Pyxis |
Pyxis Oncology Relative Risk vs. Return Landscape
If you would invest 183.00 in Pyxis Oncology on November 27, 2024 and sell it today you would lose (63.00) from holding Pyxis Oncology or give up 34.43% of portfolio value over 90 days. Pyxis Oncology is currently does not generate positive expected returns and assumes 4.0871% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Pyxis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pyxis Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pyxis Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pyxis Oncology, and traders can use it to determine the average amount a Pyxis Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1545
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PYXS |
Estimated Market Risk
| 4.09 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pyxis Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pyxis Oncology by adding Pyxis Oncology to a well-diversified portfolio.
Pyxis Oncology Fundamentals Growth
Pyxis Stock prices reflect investors' perceptions of the future prospects and financial health of Pyxis Oncology, and Pyxis Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pyxis Stock performance.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | (48.16 M) | ||||
| Shares Outstanding | 59.47 M | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 4.49 X | ||||
| EBITDA | (78.49 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 21.33 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 2.58 X | ||||
| Cash Flow From Operations | (70.71 M) | ||||
| Earnings Per Share | (1.06) X | ||||
| Total Asset | 173.73 M | ||||
| Retained Earnings | (286.23 M) | ||||
About Pyxis Oncology Performance
Assessing Pyxis Oncology's fundamental ratios provides investors with valuable insights into Pyxis Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pyxis Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people.Things to note about Pyxis Oncology performance evaluation
Checking the ongoing alerts about Pyxis Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pyxis Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pyxis Oncology generated a negative expected return over the last 90 days | |
| Pyxis Oncology may become a speculative penny stock | |
| Pyxis Oncology has high historical volatility and very poor performance | |
| Pyxis Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.79 M) with profit before overhead, payroll, taxes, and interest of 15.67 M. | |
| Pyxis Oncology currently holds about 223.36 M in cash with (70.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pyxis Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pyxis Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pyxis Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Pyxis Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pyxis Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pyxis Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pyxis Oncology's stock. These opinions can provide insight into Pyxis Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.